Literature DB >> 35396080

Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis.

Angelo Valerio Marzano1, Carlo Alberto Maronese1, Giovanni Genovese1, Silvia Ferrucci2, Chiara Moltrasio3, Riccardo Asero4, Massimo Cugno5.   

Abstract

Urticarial vasculitis (UV) is a rare cutaneous vasculitis of small vessels characterized by recurrent episodes of wheal-like lesions that tend to last more than 24 hours, healing with a residual ecchymotic postinflammatory hyperpigmentation. The histopathologic pattern of UV is that of leukocytoclastic vasculitis, consisting of fibrinoid necrosis of dermal vessels' walls and neutrophil-rich perivascular inflammatory infiltrates. Although its etiopahogenesis remains still undefined, UV is now regarded as an immune complex-driven disease with activation of the complement cascade, leading to exaggerated production of anaphylatoxins that are responsible for neutrophil recruitment and activation. This condition can be categorized into 2 main entities according to serum complement levels: normocomplementemic UV and hypocomplementemic UV, the latter being associated with circulating anti-C1q autoantibodies and possible extracutaneous manifestations. Systemic multiorgan involvement may be seen particularly in syndromic hypocomplementemic UV, also known as McDuffie syndrome. This review summarizes the clinicopathological and laboratory features as well as the underlying pathophysiological mechanisms of UV. A focus on its main differential diagnoses is provided, that is, chronic spontaneous urticaria, bullous pemphigoid, IgA (Henoch-Schönlein purpura) and IgM/IgG immune complex vasculitis, lupus erythematous tumidus, Wells syndrome, erythema multiforme, cutaneous mastocytosis, cryopyrin-associated periodic syndromes, and coronavirus disease 2019-associated and anti-severe acute respiratory syndrome coronavirus 2-vaccine-associated urticarial eruptions.
Copyright © 2022. Published by Elsevier Inc.

Entities:  

Keywords:  Urticaria; anti-C1q autoantibodies; complement; vasculitis

Mesh:

Substances:

Year:  2022        PMID: 35396080     DOI: 10.1016/j.jaci.2022.02.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   14.290


  4 in total

Review 1.  Urticaria.

Authors:  Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer
Journal:  Nat Rev Dis Primers       Date:  2022-09-15       Impact factor: 65.038

2.  Case of benralizumab-induced exacerbations of chronic spontaneous urticaria.

Authors:  Eli Magen; Irina Komarova; Israel Magen; Sofia Phirtskhalava
Journal:  Clin Case Rep       Date:  2022-06-19

3.  Efficacy and safety of omalizumab therapy in urticaria vasculitis.

Authors:  Fiorella Petrelli; Daiana Giannini; Silvia Bilia; Isabella Del Corso; Valeria Rocchi; Paola Migliorini; Ilaria Puxeddu
Journal:  Front Allergy       Date:  2022-07-22

Review 4.  Cutaneous vasculitis and vasculopathy in the era of COVID-19 pandemic.

Authors:  Carlo Alberto Maronese; Enrico Zelin; Gianluca Avallone; Chiara Moltrasio; Maurizio Romagnuolo; Simone Ribero; Pietro Quaglino; Angelo Valerio Marzano
Journal:  Front Med (Lausanne)       Date:  2022-08-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.